BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 18393144)

  • 1. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
    Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of generic low molecular weight heparins: a perspective.
    Fareed J; Leong W; Hoppensteadt DA; Jeske WP; Walenga J; Bick RL
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):53-68, v-vi. PubMed ID: 15639108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
    Walenga JM; Jackson CM; Kessler CM
    Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The United States Food and Drugs Administration approves a generic enoxaparin.
    Ofosu FA
    Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
    Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
    Ofosu FA
    Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human pharmacokinetics of low molecular weight heparins.
    Cornelli U; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():57-61. PubMed ID: 10549717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are the available low-molecular-weight heparin preparations the same?
    Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
    Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of low molecular weight heparins in animal models.
    Fareed J; Fu K; Yang LH; Hoppensteadt DA
    Semin Thromb Hemost; 1999; 25 Suppl 3():51-5. PubMed ID: 10549716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
    Harenberg J
    Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic equivalence of complex drugs.
    Schellekens H; Klinger E; Mühlebach S; Brin JF; Storm G; Crommelin DJ
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):176-83. PubMed ID: 20951177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative human pharmacology of low molecular weight heparins.
    Harenberg J; Stehle G; Augustin J; Zimmermann R
    Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.